Literature DB >> 25981217

Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experience.

F Petitpierre1, F Cornelis2, L Couzi3, A S Lasserre1, E Tricaud1, Y Le Bras1, P Merville3, C Combe4, J M Ferriere4, N Grenier1.   

Abstract

PURPOSE: We aimed to retrospectively assess the long-term safety and efficacy of embolization of renal arteries (ERA) in patients with polycystic kidney disease (PKD) before renal transplantation.
MATERIAL AND METHODS: Between January 2008 and November 2013, 82 ERA procedures were performed on 76 kidneys in 73 patients (mean age 53 years, range: 34-72). All patients had terminal-stage PKD and were under dialysis and on the renal transplant waiting list with a temporary contraindication due to excessive renal volume.
RESULTS: ERA was considered successful in 89.5% (68/76) of embolized kidneys, meaning that the temporary contraindication for transplantation could be withdrawn for 65 patients (on average 5.6 months, range: 2.8-24.3, after ERA). Mean volume reduction was 40 (range: 2-69) at 3 months and 59% (35-86) thereafter (both p < 0.001). Post-embolization syndrome occurred after 15 of 82 procedures (18.3%). The severe complication rate was 4.9%. Forty-three (67.7%) transplantations were successfully conducted after ERA, with a mean follow-up of 26.2 months (range: 1.8-59.5), and the estimated 5-year graft survival rate was 95.3% [95% CI: 82.7-98.8].
CONCLUSIONS: ERA is a safe and effective alternative to nephrectomy before renal transplantation in patients with PKD. KEY POINTS: • Embolization of non-functioning polycystic kidneys allowed transplantation in 89.5% of cases. • Technical failure rate was 7.9% after embolization, irrespective of the technique used. • Post-embolization syndrome occurred after 18.3% of the procedures. • A low rate of severe complications (4.9%) was observed after renal embolization.

Entities:  

Keywords:  Embolization; Polycystic Kidney Disease; Safety; Survival; Transplantation

Mesh:

Year:  2015        PMID: 25981217     DOI: 10.1007/s00330-015-3730-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

Review 2.  Renal artery embolization for the symptomatic treatment of adult polycystic kidney disease.

Authors:  Matthew S Bremmer; Stephen C Jacobs
Journal:  Nat Clin Pract Nephrol       Date:  2008-03-04

3.  Concurrent unilateral or bilateral native nephrectomy in kidney transplant recipients.

Authors:  Ayhan Dinckan; Huseyin Kocak; Ahmet Tekin; Serdar Turkyilmaz; Necmiye Hadimioglu; Zeki Ertug; Filiz Gunseren; Erhan Ari; Bulent Dinc; Alihan Gurkan; Selcuk Yucel
Journal:  Ann Transplant       Date:  2013-12-20       Impact factor: 1.530

4.  Is preliminary binephrectomy necessary in patients with autosomal dominant polycystic kidney disease undergoing renal transplantation?

Authors:  B L Rayner; M J Cassidy; J E Jacobsen; M D Pascoe; A R Pontin; R van Zyl Smit
Journal:  Clin Nephrol       Date:  1990-09       Impact factor: 0.975

5.  Transcatheter infarction of a polycystic kidney for control of recurrent hemorrhage.

Authors:  J D Harley; F H Shen; S J Carter
Journal:  AJR Am J Roentgenol       Date:  1980-04       Impact factor: 3.959

6.  Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study.

Authors:  Antoine Jacquet; Nicolas Pallet; Michèle Kessler; Maryvonne Hourmant; Valérie Garrigue; Lionel Rostaing; Henri Kreis; Christophe Legendre; Marie-France Mamzer-Bruneel
Journal:  Transpl Int       Date:  2011-02-26       Impact factor: 3.782

Review 7.  Angiogenesis and autosomal dominant polycystic kidney disease.

Authors:  Jennifer L Huang; Adrian S Woolf; David A Long
Journal:  Pediatr Nephrol       Date:  2012-09-19       Impact factor: 3.714

8.  Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation?

Authors:  Matthew A Kirkman; David van Dellen; Sanjay Mehra; Babatunde A Campbell; Afshin Tavakoli; Ravi Pararajasingam; Neil R Parrott; Hany N Riad; Lorna McWilliam; Titus Augustine
Journal:  BJU Int       Date:  2010-12-16       Impact factor: 5.588

9.  The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

Authors:  F Qian; T J Watnick; L F Onuchic; G G Germino
Journal:  Cell       Date:  1996-12-13       Impact factor: 41.582

10.  Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure.

Authors:  Amedeo F De Vecchi; Patrizia Colucci; Francesco Salerno; Antonio Scalamogna; Claudio Ponticelli
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860

View more
  4 in total

1.  Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Koki Mise; Toshiharu Ueno; Keiichi Sumida; Masayuki Yamanouchi; Noriko Hayami; Junichi Hoshino; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi
Journal:  J Am Soc Nephrol       Date:  2015-11-30       Impact factor: 10.121

Review 2.  ADPKD: clinical issues before and after renal transplantation.

Authors:  Piergiorgio Messa; Carlo Maria Alfieri; Emanuele Montanari; Mariano Ferraresso; Roberta Cerutti
Journal:  J Nephrol       Date:  2016-10-20       Impact factor: 3.902

Review 3.  Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues.

Authors:  Tatsuya Suwabe
Journal:  Clin Exp Nephrol       Date:  2020-07-22       Impact factor: 2.801

Review 4.  Use of angioembolization in urology: a review.

Authors:  Kirkpatrick B Fergus; Nima Baradaran; Anas Tresh; Miles B Conrad; Benjamin N Breyer
Journal:  Transl Androl Urol       Date:  2018-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.